Form 4: Immunovant Director George V. Migausky Reports Acquisition of Stock Options and Restricted Stock Units

Director George V. Migausky reports acquisition of stock options and restricted stock units in Immunovant, Inc.

Summary

• On April 1, 2025, George V. Migausky, a director of Immunovant, Inc., acquired 16,188 restricted stock units (RSUs) and 7,600 stock options.
• The RSUs were granted under the company's 2019 Equity Incentive Plan and represent the right to receive one share of common stock upon vesting.
• The RSUs will vest on April 1, 2026, contingent upon the director's continued service to the Issuer.
• The director also acquired options to purchase 7,600 shares of common stock at an exercise price of $15.20, which also vest on April 1, 2026, subject to continued service.
• Following these transactions, Migausky directly owns 7,600 derivative securities and 137,251 shares of Immunovant common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard equity compensation practices, aligning director interests with shareholders. There are no indications of negative events or concerns.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting conditions tied to continued service incentivize the director to remain with the company.

Future Outlook

The vesting of the RSUs and stock options is contingent upon the Reporting Person's continuous service to the Issuer as of April 1, 2026.

Industry Context

This filing is a routine disclosure related to equity compensation for a company director, which is a common practice in the biotechnology industry to align management's interests with those of shareholders.

Comparison to Industry Standards

• Equity compensation for directors is a standard practice across the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options and restricted stock units as part of their director compensation packages.
• The vesting schedules and amounts granted are generally benchmarked against peer companies to ensure competitiveness and alignment with performance.

Stakeholder Impact

• The grant of equity to a director can positively impact shareholders by aligning management's interests with the company's long-term success.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Immunovant, Director, Migausky, Stock Options, RSUs, Form 4, Beneficial Ownership, Equity Incentive Plan